Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2005
12/01/2005CA2563735A1 Antibodies and molecules derived therefrom that bind to steap-1 proteins
12/01/2005CA2563432A1 Method for augmenting b cell depletion
12/01/2005CA2508585A1 Transdermal delivery system for treatment of cognitive disorders
11/2005
11/30/2005EP1600507A1 Cis-element regulating transcription, transcriptional regulatory factor binding specifically thereto and use of the same
11/30/2005EP1600180A2 Antiproliferative drug and delivery device
11/30/2005EP1600169A2 A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
11/30/2005EP1600168A2 A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
11/30/2005EP1600167A2 A pyrrolidineacetamide derivative alone in combination for treatment of CNS disorders
11/30/2005EP1600166A1 Skeletal muscle protecting agent
11/30/2005EP1600160A1 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
11/30/2005EP1600156A2 Combination treatment for impaired motor function in parkinson's disease
11/30/2005EP1600143A1 SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE
11/30/2005EP1600061A1 Oral and/or topical compositions
11/30/2005EP1599217A2 Methods for inhibiting viral replication in vivo
11/30/2005EP1599212A2 Combination therapy for the treatment of immunoinflammatory disorders
11/30/2005EP1599210A1 A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
11/30/2005EP1599204A2 Selective mglu5 antagonists for treatment of neuromuscular dysfunction of the lower urinary tract
11/30/2005EP1599202A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
11/30/2005EP1599199A2 Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
11/30/2005EP1599198A1 Potassium taurate bicarbonate and ascorbate complexes
11/30/2005EP1599196A2 Combination therapies for the treatment of cancer
11/30/2005EP1599194A1 Use of active ingredients for the prophylaxis and/or therapy of viral diseases
11/30/2005EP1599175A2 Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders
11/30/2005EP1599172A2 Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
11/30/2005EP1599169A2 Method for increasing hair growth
11/30/2005EP1599128A2 Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
11/30/2005EP1432708B1 Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity
11/30/2005EP1392702B1 Compounds and methods for inhibiting mrp1
11/30/2005EP1317483B1 Variants of allergenic proteins of the group 2 of dermatophagoides
11/30/2005EP1313488A4 Compositions and methods for improving cardiovascular function
11/30/2005EP1282439B1 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR
11/30/2005EP1274457B1 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
11/30/2005EP1252179B1 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them
11/30/2005EP1207809A4 Metering and packaging of controlled release medication
11/30/2005EP1194436B1 Sulfonamidomethyl phosphonate inhibitors of beta-lactamase
11/30/2005EP1192268B1 Nucleic acid binding of multi-zinc finger transcription factors
11/30/2005EP1176981B1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/30/2005EP1156787B1 Oxadiazole compounds and compositions for delivering active agents
11/30/2005EP1144372B1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
11/30/2005EP1140010B1 Composition and method of sequestration of skin irritants.
11/30/2005EP1079832B1 Use of vitamin pp compounds
11/30/2005EP1003487B1 Pharmaceutical formulation with controlled release of active substances
11/30/2005EP0963200B9 Compositions for inhibition of angiogenesis comprising thalodomide and a nsaid
11/30/2005CN1703420A Promoters exhibiting endothelial cell specificity and methods of using same
11/30/2005CN1703416A Methods and compositions comprising nitric oxide donors and opioid analgesics
11/30/2005CN1703245A Association between a heterocyclic compound stimulating lipid and carbohydrate metabolisms and an antioxidant agent for treating obesity
11/30/2005CN1703244A Association between a PPAR ligand and an antioxidant agent and use thereof for treating obesity
11/30/2005CN1703227A Methods and compositions for treatment of neurological disorder
11/30/2005CN1703226A Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
11/30/2005CN1703224A Therapeutic treatment
11/30/2005CN1703218A Combinations of benzodithiazoles and COx-2 inhibitors for the treatment of pain
11/30/2005CN1703216A Epothilone derivatives for the treatment of multiple myeloma
11/30/2005CN1703208A EPO D+5-fu/gemcitabine
11/30/2005CN1703207A Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3 betta
11/30/2005CN1703206A Plaster for the treatment of dysfunctions and disorders of nail growth
11/30/2005CN1703197A Injectable depot compositions and uses thereof
11/30/2005CN1703175A Implantation of encapsulated biological materials for treating diseases
11/30/2005CN1703147A Full range nutritional supplements from plant materials and methods for their manufacture
11/30/2005CN1229646C Catalytic anti-factor VIII allo-antibodies
11/30/2005CN1229370C Novel derivatives of flavones, xanthones and coumarins
11/30/2005CN1229335C Nervinolin derivatives
11/30/2005CN1229142C NSAID and EFGR kinase inhibitor contg. compsn. for treatment or inhibition of colonic polyps and colorectal cancer
11/30/2005CN1229141C Combination therapy of angiotension converting enzyme inhibitor and epoxy-steroidal aldosterone anatagonist for treatment of cardiovascular disease
11/30/2005CN1229140C Targeted anticarious DNA vaccine and peparation thereof
11/30/2005CN1229137C New therapeutic uses of SMR1 peptides
11/30/2005CN1229113C A Pharmaceutical composition for the treatment of autoimmune diseases
11/30/2005CN1229110C Ophthalmic compositions containing galactomannan polymers and borate
11/29/2005US6969719 Such as 3-((3-bromo-4-hydroxyphenyl)methyl)-5-ethyl-7,8-dihydro-2-(tetrahydro-2H -pyran-4-yl)amino)-3H-imidazo(2,1-b) purin-4(5H)-one for treating sexual disorders
11/29/2005US6969718 17-β hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
11/29/2005US6969717 Azaindole kinase inhibitors
11/29/2005US6969715 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
11/29/2005CA2355493C Therapeutic compositions comprising excess enantiomer
11/29/2005CA2326660C Method for producing transdermal therapeutic systems by using basic alkali metal salts for converting active agent salts into free bases
11/24/2005WO2005110494A2 Methods and compositions for the inhibition of thrombus formation
11/24/2005WO2005110484A2 Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration
11/24/2005WO2005110483A2 Use of targeted oxidative therapeutic formulation in bone regeneration
11/24/2005WO2005110482A1 Percutaneous pharmaceutical preparation for external use containing nonsteroidal antiinflammatory analgesic
11/24/2005WO2005110481A2 Prolongation of survival of an allograft by inhibiting complement activity
11/24/2005WO2005110480A2 Combination of organic compounds
11/24/2005WO2005110479A2 Treatments for pancreatic cancer
11/24/2005WO2005110478A2 Combination therapy for treating fibrotic disorders
11/24/2005WO2005110477A2 Combination therapies for cancer and proliferative angiopathies
11/24/2005WO2005110476A1 Method of inhibiting telomerase activity and inhibitor
11/24/2005WO2005110464A2 Irx5 inhibition as treatment for hyperproliferative disorders
11/24/2005WO2005110442A2 Peritoneal dialysis solution
11/24/2005WO2005110438A2 Methods and products related to the intracellular delivery of polysaccharides
11/24/2005WO2005110411A1 Combinations of substituted 1-phenyl-1,5-dihydro-pyrido- [3,2-b] indol-2-ones and other hiv inhibitors
11/24/2005WO2005110408A1 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
11/24/2005WO2005110403A1 The non-opiate heroin withdrawal medicines
11/24/2005WO2005110394A1 Therapeutic agent for diabetes
11/24/2005WO2005110388A1 Use of targeted oxidative therapeutic formulation in treatment of cancer
11/24/2005WO2005110375A1 Nutritional supplement for treatment of ocular diseases
11/24/2005WO2005110353A1 Personal care compositions and methods for regulating mammalian hair growth and skin condition
11/24/2005WO2005110085A2 Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
11/24/2005WO2005110022A2 Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
11/24/2005WO2005060951A3 Anti-neoplastic agents, combination therapies and related methods
11/24/2005WO2005058295A3 Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
11/24/2005WO2005052119A3 Adjuvants of immune response
11/24/2005WO2005039637A3 Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker
11/24/2005WO2004103271A3 Disease prevention and vaccination prior to thymic reactivations
1 ... 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 ... 1151